We would love to join!

Happening tomorrow! We're looking forward to seeing you at the Optimal Care Pathway for Lung Cancer in an Evolving Field Workshop. Registrations/lunch from 12:00pm.

One week until the inaugural #ESMOTATAsia25 🤩 I'm looking forward to joining global drug development experts in🍜🇭🇰 + sharing insights on dose optimisation of novel combinations 🗓️ Saturday 19 July 2pm. @myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

📘 Just launched: the first-ever clinical casebook focused solely on immune-related toxicities. 65 expert-contributed cases across 10+ organ systems. Essential reading for the #irAE frontlines. Grab your copy 👉 link.springer.com/book/10.1007... #irAE #OncologyBooks @ascocancer.bsky.social #ASPIRE

Was chatting to my registrar about transitioning to life as a new consultant 🤩remembered @theracp.bsky.social has a handbook on this! www.racp.edu.au/docs/default... What are your top tips? #MedEd #Newfaculty

🚀 That's a wrap #ASCO25! Join ASCO’s #ASPIRE Community of Practice, the go-to hub for clinicians addressing immune-related toxicities! 🌟 FREE access for non-oncologists (for a limited time) 💬 Engage in virtual meetings, expert discussions, and access curated content! docs.google.com/forms/d/1zfl...

Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE

Such important work @aspire-cop.bsky.social team. Crucial to collect the right info to improve our understanding of immunotherapy toxicities and plan the right supportive care for our patients #IOtox #supportivecare #immunotherapy

Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social

🌟Calling all #ASCO25 presenters!🌟 Are you showcasing an #irAE poster? #ASPIRE wants to spotlight your incredible work! 🙌 Join us in advancing knowledge in this vital field!✨ @ascocancer.bsky.social @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @oncoalert.bsky.social

🌟 Got questions about #irAEs? 🤔 What about tumor deposits in the lung or liver—do they heighten the risk? Recent retrospective data from hospitalized patients suggests an association 🚨 jitc.bmj.com/content/13/5... #ASPIRE @aspire-cop.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social

📣 #ESMOFellowship: Check out the practical tips from Teresa Amaral and Evandro de Azambuja on how to make your application stand out. 📅 Apply by 29 May 2025 at 12.00 AM CEST 🔗 ow.ly/ANRS50VVret

Blessed to have mentors who are the driving force of lung cancer research in New Zealand @anmwongnz.bsky.social & Laird Cameron. #NewZealand #LCSM #Oncsky

Super proud of our team Drs Laird Cameron, Sandra Fitzgerald getting our 1st Auckland patient into our FAST 🫁 🧬 ctDNA study today 🤩🤩🤩 Laird & I first dreamed up the study while at @myesmo.bsky.social Asia Singapore Dec22!!! Good things take time ❤️ so fun to do research w one of my besties!

Early bird registrations are open for TOGA's 2025 ASM! The theme of this year’s hybrid event is ‘Implementing Change in Thoracic Cancer Care Through Multidisciplinary Innovation’, with a special focus on bringing evidence-based solutions into practice using implementation science.

Beyond excited about Pharmac’s proposed melanoma drug funding from 1st June! 🙏🙏🙏Alex van Akkooi @melanomaau.bsky.social & Hannah Farnsworth @petermaccc.bsky.social for sharing their surgical and nursing experience in Melnet’s virtual session on perioperative melanoma management next Tuesday.

Get ready to hear from Kelvin Lau, presenting on Robot Assisted Endobronchial Intervention at the 2025 TOGA ASM! Don't miss this chance to hear from leading experts. 📅 Save the date: July 30 – August 1 📍 Location: Brisbane Convention & Exhibition Centre Check out the program > buff.ly/7YecVX1

Felt so honoured to be gifted this Māori taonga (treasure) after an uplifting day at the marae: learning with our community cancer navigators & our cancer support team! A sacred symbol of our collaboration, united together for our patients & whanau ❤️ 🙏TY for invite! #maoriculture #oncology #MedEd

🎙️It's not one size fits all with cancer care. We're trying to make a customized plan & [rally] all of the modern technologies to make sure that we're rightsizing the treatments for the individual. And I think that provides a lot of benefits for patients. #breastCancer #bcsm @ascocancer.bsky.social

NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 meetings.asco.org/abstracts-pr... #NCT03576417 #hncsm #ImmunoOnc

⏰Less than 2 weeks left to submit your abstract to #ESMOTATAsia25! A fantastic opportunity to showcase your transformative work within the region in a truly international platform. 👉Submit your research by 29 April by 18:00 Hong Kong Time 🔗 buff.ly/nOD4Kzs

Bipartisan bill seeks to reform prior authorization @thehill.com @ascocancer.bsky.social thehill.com/policy/healt...

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We're grateful for their extraordinary commitment. asco.org/about-asco/a... @adesaimd.bsky.social @pgrivasmdphd.bsky.social @sagarlonialmd.bsky.social @pateloncology.bsky.social

Huge news for patients in nz with melanoma! Government funding for: 🤩perioperative Pembrolizumab for resectable stage III 🤩Dabrafenib and Trametinib adjuvant and metastatic setting

What an inspiring video to wake up to! 🙌find strength in your team 🙌defend what is right 🙌you can do ANYTHING but not everything 🙌fight imposter syndrome - you deserve to be there youtu.be/i6fe2EK2lh8?... @solangepeters.bsky.social @drjnaidoo.bsky.social #ESMO #Women4Oncology #oncology

9.5% MET and 7.9% EGFR detected in pts w lung SqCC with no smoking history. Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease. #lcsm

We still have a long way to go to ensure that ALL patients benefit from recent scientific advances in #lungcancer. This study found that overall survival increased by 71% in patients with private insurance compared to only 24% in the uninsured in the US. #LCSM www.jtocrr.org/article/S266...

Final clinic 2024! Thank you @narjustflorezmd.bsky.social and team for driving the #HearHer #Icsm campaign ... your pin has finally reached the end of the world to 🇳🇿 New Zealand! Excited to ring in 2025 with more global collaborations for 🫁 lung cancer!

🩸🧬Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology! @oncoalert.bsky.social @christianrolfo.bsky.social @viveksubbiah.bsky.social www.annalsofoncology.org/action/showP...

Feeling inspired already on ✈️ to ESMO Asia 🇸🇬 to catch up with friends and colleagues See you there!

Surgical resectability for locally advanced #LungCancer redefined - Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments. From STS #LCSM #SurgSky #MedSky #CancerSky www.annalsthoracicsurgery.org/article/S000...

New Zealand National Oncology Bake Off today in Christchurch. Supreme winner was ‘Cake-citabine’ from Wellington Regional Hospital. #oncsky #medsky #cake

Our med onc trainees took home the national Trainees Day Bake off this year with their cake-citabine cupcakes creation Couldn’t be more proud! 🤩🤩🤩 #CRCSM #MedEd #Oncsky #cansky #wellington

One of the hardest things for patients with brain metastases is inability to drive FYI NZ transport assoc has updated guidelines for medical fitness to drive Pertinent for pts w brain mets, 🧠 Solitary met - may 🚗 1 year if stable 🧠 Multiple Mets - may 🚗after 2 yrs if stable

Review: The present and future of bispecific antibodies for cancer therapy

⏰ Final call! 🧑‍🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester To apply (deadline 1 Dec 2024): www.cruk.manchester.ac.uk/recruitment/...

I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology www.esmorarecancers.org/article/S305...

added to go.bsky.app/GKXp9Fy. please pass the word to colleagues

Added you to go.bsky.app/UP8aWPd please share and suggest others.

Top barriers to liquid biopsy adoption: 🩸reimbursement (54%), 🩸false negatives (44%), 🩸limited clinical data (32%). Addressing these challenges is critical. @christianrolfo.bsky.social @oncoalert.bsky.social

🎨 In case anyone need… The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏! Check it out 👇 bioart.niaid.nih.gov

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...

Both #Cancer #Research starter packs are now completely full! ~300 researchers, oncologists, students, postdocs, patient advocates, and organizations supporting cancer research 🧪🔬⚕️ I hope you'll find these useful to build our community here Pack 1: go.bsky.app/FEoaJMc Pack 2: go.bsky.app/6EcjWNA

Thanks for the reminder! @drdonsdizon.bsky.social #cansky #oncsky #MedEd #SoMe

New this month in JCO Oncology Practice 🔥 - Special issue on Molecular Testing in Oncology Practice - great papers on the science, use in select diseases, and ethics of testing as the science evolves. #cancer ascopubs.org/doi/10.1200/...

Starting a list of oncology related peopl. Please tell me more to add. Or any similar listd go.bsky.app/GKXp9Fy @n8pennell.bsky.social

If anyone is looking for a good primer on precision oncology for #NSCLC, I recommend this article. Clear and well communicated. Useful comments on emerging biomarkers, role of #liquidbiopsy, and #NGS vs sequential testing #oncsky #medsky #lungcancer doi.org/10.1200/OP.2...

go.bsky.app/4d7SDyn Who else would be in your Oncology Education starter pack? @drjnaidoo.bsky.social @tmprowell.bsky.social @oncoalert.bsky.social

Well that was easy 😅